Ulcerative colitis does affect pregnancy, but the single biggest factor in how much it affects pregnancy is whether the disease is active or in remission at the time of conception. Women who conceive during remission have outcomes very close to those of the general population. Women who conceive during active disease face significantly higher rates of preterm birth, low birth weight, and flares that worsen as pregnancy progresses.
Why Disease Activity at Conception Matters Most
A retrospective study comparing pregnancies in women with active UC versus those in remission found that 18.2% of women with active disease delivered prematurely, compared to 5% of those in remission. Low birth weight occurred in 36.4% of the active disease group versus 12.5% of the remission group. These numbers tell a clear story: the state of your UC when you get pregnant sets the trajectory for the entire pregnancy.
The pattern continues after conception too. In one cohort study tracking disease activity through pregnancy, only 2.4% of women had active disease at the time of conception, but that number climbed steadily: 4.4% in the first trimester, 7.8% in the second, and 16.5% by the third trimester. About 32% of women with inflammatory bowel disease experienced a flare within the first year after delivery, and UC accounted for 60% of those postpartum flares. Pregnancy itself doesn’t reliably calm the disease, and the postpartum period carries its own risk of relapse.
The Three-Month Remission Window
Current expert consensus recommends achieving at least three months of steroid-free remission before attempting conception. The “steroid-free” part is important. Being in remission only because you’re taking corticosteroids doesn’t count, because steroids carry their own pregnancy risks and signal that the disease isn’t truly under control. A 2023 study confirmed that women who met this three-month steroid-free threshold before conception had better outcomes for both themselves and their babies.
This means pregnancy planning with UC ideally starts well before conception. If you’re currently on steroids or experiencing symptoms, the goal is to work with your gastroenterologist to switch to a maintenance therapy that keeps the disease quiet on its own, then wait at least three months in that stable state before trying to conceive.
Which Medications Are Safe During Pregnancy
One of the most common fears is that UC medications will harm the baby, and this fear leads some women to stop treatment on their own. That decision often backfires: uncontrolled inflammation poses a greater risk to the pregnancy than most UC medications do.
Biologic therapies (the injectable or infusion-based medications that target the immune system) have been studied extensively in pregnancy. A large systematic review and meta-analysis found that biologic use during pregnancy was not associated with an increased overall risk of infections in infants. There was a modest increase in upper respiratory infections in exposed infants, but no significant increase in ear infections, urinary tract infections, gastrointestinal infections, antibiotic use, or infection-related hospitalizations. Continuing biologics through the third trimester did not add additional infection risk beyond earlier exposure.
These medications do cross the placenta and can be detected in infants, sometimes for months after birth. One study found that immune cell patterns in exposed newborns looked slightly more immature at birth but normalized by six months as the medication cleared. The main practical concern is live vaccines: because traces of immune-suppressing medication may linger in the baby, live vaccines like BCG (used in some countries for tuberculosis) should be delayed. A fatal infection was reported in one infant who received BCG vaccination after in-utero exposure to a biologic, which is why pediatricians need to know about your medications.
Methotrexate is the major exception. It causes birth defects and must be stopped at least three months before conception. Sulfasalazine is generally considered safe but interferes with folic acid absorption, so women taking it need a higher daily folic acid dose of 5 mg rather than the standard prenatal amount. European guidelines recommend that all women with IBD take at least 1 mg of folic acid daily when planning pregnancy.
How UC Affects Fertility
UC itself, when well controlled with medication, does not significantly reduce fertility. The picture changes dramatically after surgery. Women who undergo a total colectomy with creation of an internal pouch (the procedure that removes the colon and builds a reservoir from the small intestine) face roughly four times the risk of infertility compared to before surgery. A meta-analysis of 13 studies found that infertility rates reached nearly 43% after pouch surgery, compared to about 13% before it.
The cause is scarring and adhesions in the pelvis from open abdominal surgery, which can block or distort the fallopian tubes. Minimally invasive surgical approaches reduce this problem. One study found that 55% of women who had laparoscopic pouch surgery conceived within 12 months of trying, compared to 35% in the open surgery group. Laparoscopy was also associated with shorter time to conception. For women who do experience post-surgical infertility, IVF is an option, though success rates are lower in women whose pouch has failed compared to other UC patients.
Delivery: Vaginal Birth vs. C-Section
Most women with UC can deliver vaginally. The two situations where a cesarean delivery is specifically recommended are active perianal disease (inflammation, fissures, or abscesses around the anus at the time of delivery) and the presence of a surgical pouch. The concern with vaginal delivery in pouch patients is potential damage to the anal sphincter, which could lead to long-term incontinence or pouch dysfunction. Guidelines describe this as a conditional recommendation, meaning it should be discussed on a case-by-case basis with your gastroenterologist and obstetrician rather than treated as an absolute rule.
Will Your Child Develop UC?
Parents with UC naturally wonder about passing the condition to their child. UC does have a genetic component, but the absolute risk to any individual child remains relatively low. A large population-based study from South Korea found that the incidence of UC among children of affected mothers was about 45 per 100,000 person-years, and about 35 per 100,000 for children of affected fathers, compared to roughly 5 per 100,000 in people with no family history. That translates to a risk roughly 7 to 9 times higher than the general population, which sounds dramatic in relative terms but still means the vast majority of children born to a parent with UC will not develop the disease.
When both parents have UC, the risk climbs to about 13 times that of having one affected parent. This scenario is uncommon, but couples where both partners have UC should be aware of the substantially elevated hereditary risk.
Nutrition and Supplements
Folic acid supplementation is especially important for women with UC planning pregnancy. Standard prenatal vitamins contain 400 to 800 micrograms of folic acid, but European guidelines recommend at least 1 mg daily for all women with IBD. Women taking sulfasalazine need 5 mg daily because the drug actively interferes with folic acid metabolism. Since folic acid is critical for preventing neural tube defects in the earliest weeks of pregnancy, this higher dose should start before conception.
Iron deficiency is also common in UC due to chronic intestinal bleeding and poor absorption. Pregnancy increases iron demands substantially, so monitoring iron levels and supplementing as needed helps prevent the compounding effect of UC-related and pregnancy-related anemia.